Short term human studies have not identified major safety signals at studied doses, but long term (multi year) safety data does not exist. Because it stimulates endogenous GH release, theoretical concerns around GH's known effects (insulin sensitivity changes, potential growth factor driven proliferation effects) apply, supporting physician supervised use rather than self directed protocols. RUO sourced product quality is not independently verified.

What is the dose of Ipamorelin?

No established consumer dosing protocol; see full guide article for regulatory and safety context.

Compound Profile

Ipamorelin

Growth hormone secretagogue (ghrelin receptor agonist) peptide

Ipamorelin is a selective ghrelin receptor agonist (growth hormone secretagogue) with more human clinical data than most peptides in this class, showing reliable dose dependent GH release with minimal cortisol/prolactin cross reactivity; downstream body composition and sleep claims are more extrapolated than proven.

Last reviewed: June 30, 2026

C Preliminary

Monograph visual

Ipamorelin

Generated profile category visual

Where to go next — guides & comparisons

If you want help sleeping → Sleep guides
If you want help with anxiety or stress → Anxiety & stress guides
If you want to browse more compounds → All compounds

Unapproved compound: FDA reclassification pending

Ipamorelin is not FDA-approved as a finished drug product. It was named among peptides expected to move toward Category 1 (compoundable) status per the February 2026 HHS/FDA announcement, but formal Federal Register rulemaking confirming its final category had not yet published as of mid-2026.

No prescription form of Ipamorelin exists on the market; product is research-use-only (RUO) or physician-prescribed compounded where accessible.
Prohibited under WADA’s S2 category for competitive athletes.
This profile is not a self-treatment guide.

Regulatory status

2026 federal and state regulatory context

Last checked 2026 06 30

No prescription form exists on the market; product is RUO or physician prescribed compounded (where accessible). Prohibited under WADA's S2 category for competitive athletes.

Regulatory changelog

2026 02: Named among ~14 of 19 originally Category 2 restricted peptides expected to move back toward Category 1 per HHS/FDA announcement. Mid 2026: Formal Federal Register rulemaking confirming final category not yet published.

Quick Stats

Evidence level

Preliminary evidence

Typical onset

Varies by prep

Safety rating

Use extra caution: Safety review pending

Best for

Ghrelin Receptor (GHS R1a) Agonism, Selective Pulsatile GH Release, Minimal Cortisol/Prolactin Cross Reactivity

Avoid / review if

Pregnancy/Breastfeeding, Uncontrolled Diabetes, Unsupervised RUO Product Use Without Physician Oversight

Safety & Cautions

Review before use if any apply: Pregnancy/Breastfeeding, Uncontrolled Diabetes, Unsupervised RUO Product Use Without Physician Oversight.

Evidence-based safety

Caution when combined

These pairings share a flagged risk mechanism. They are additive-effect cautions derived from contraindication data, not confirmed clinical interactions. Consult a clinician before combining.

Moderate Caution

110 flagged pairings

Blood-sugar lowering

Browse the grouped cautions below. The list scrolls inside this card when long.

Blood-sugar lowering

Evidence Summary

C Preliminary

Evidence lens

Useful signal, but study design, dose, and population still matter.

ModeratePreliminary evidence

Human clinical evidence: Present in source signals

Mechanistic / preclinical: Mechanism mapped — Ghrelin Receptor (GHS R1a) Agonism · Selective Pulsatile GH Release · Minimal Cortisol/Prolactin Cross Reactivity

Research maturity: More interpretable — main contexts: Ghrelin Receptor (GHS R1a) Agonism · Selective Pulsatile GH Release · Minimal Cortisol/Prolactin Cross Reactivity

Safety boundary: Safety note available — Review before use if any apply: Pregnancy/Breastfeeding, Uncontrolled Diabetes, Unsupervised RUO Product Use Without Physician Oversight.

Evidence Strength

Confidence estimate based on the design quality and consistency of published clinical trials.

Preliminary evidence

Ipamorelin has a preliminary evidence evidence rating.

Sleep SupportSleep

Effects

How evidence grades work

Each grade reflects the strength and consistency of published human evidence — not marketing claims. Grades are based on study count, design quality, effect size, consistency, and recency.

Strong

Multiple RCTs, consistent direction, adequate effect size

Moderate

Some RCTs or consistent observational data in humans

Preliminary / Mixed

Animal or in-vitro only, or conflicting human data

Traditional / Theoretical

Traditional use only; no controlled human trials

How Ipamorelin Works

Simplified mechanism pathway based on preclinical and pharmacological evidence. Does not confirm clinical efficacy.

Mechanism Pathway — How Ipamorelin Works

CompoundTarget / ReceptorMechanismEffect / Outcome

Mechanisms & Biological Pathways▼

Preclinical mechanism details from scientific profiles; these represent plausible pathways but do not guarantee clinical efficacy in humans.

Ghrelin Receptor (GHS R1a) AgonismSelective Pulsatile GH ReleaseMinimal Cortisol/Prolactin Cross ReactivityGrowth Hormone AxisIGF 1 Signaling

Compare & Sourcing

Compare side-by-side tradeoffs or verify active marker guidelines.

Free safety checklist

Get the Ipamorelin evidence notes

Occasional research updates, safety context, and product-quality checks for supplement decisions.

We use your email to send the checklist and occasional evidence-first supplement updates. Unsubscribe anytime. Privacy policy.

⚠️ Sourcing Options Disabled for Safety

Direct product recommendations and affiliate links are suppressed for this compound due to its high caution or needs-review safety classification.

Evaluate the safety checks, contraindications, and potential medication interactions below under clinician supervision before use.

Safety first · Harm reduction

This information is educational and not medical advice. Start low, avoid risky combinations, and consult a licensed clinician before making health decisions—especially if you use medications, have diagnosed conditions, or are pregnant/breastfeeding.

Learn how we evaluate confidence, safety, and intensity on the methodology page.

Editorial Review

Checked against primary sources, cited evidence, and contraindication language before publication. Evidence claims, safety language, and affiliate modules are reviewed independently. Not personal medical advice.

Editorial Standards →

← Back to compounds library Safety checker →

Compound profile context

How to interpret Ipamorelin

Ipamorelin dosage by use case, onset and duration, safety limits, and interactions for ghrelin receptor (ghs r1a) agonism, graded against research.… Use this compound profile to understand mechanism, evidence quality, and practical safety context before comparing products or building a stack. A biochemical pathway connection can be useful for discovery, but it is not the same as proven benefit in humans.

When reviewing Ipamorelin, separate the active molecule from the product category around it. Dose form, absorption, extract standardization, medication interactions, and individual sensitivity can change the real-world risk-benefit picture.

For supplement planning, avoid combining multiple compounds with overlapping sedating, stimulating, serotonergic, blood-pressure, anticoagulant, or liver-metabolism effects unless a qualified clinician has reviewed the context.